| Dr Bradford Craig Lipman, MD | |
|
1605 Roberta Dr Sw, Marietta, GA 30008-3855 | |
| (770) 419-3120 | |
| Not Available |
| Full Name | Dr Bradford Craig Lipman |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 1605 Roberta Dr Sw, Marietta, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740285956 | NPI | - | NPPES |
| 000317358STUVWAAABAC | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 028596 (Georgia) | Primary |
| Entity Name | Good Samaritan Health Center Of Cobb |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881923126 PECOS PAC ID: 7214970482 Enrollment ID: O20050608000595 |
News Archive
As critical care professionals develop a better understanding of the progression of H1N1, they are becoming better prepared to treat children with severe cases, according to a new study that will be published in the March issue of Pediatric Critical Care Medicine (PCCM).
Apria Healthcare Group Inc. (the "Issuer") announced today that it is commencing exchange offers for all of its outstanding 11.25% Senior Secured Notes due 2014 (Series A-1) (the "Outstanding Series A-1 Notes") and 12.375% Senior Secured Notes due 2014 (Series A-2) (the "Outstanding Series A-2 Notes" and, together with Outstanding Series A-1 Notes, the "Outstanding Notes"), upon the terms and conditions set forth in a prospectus, dated August 16, 2010, and in the accompanying letter of transmittal relating to the exchange offers.
Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
Nile Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that it has completed the dosing of the last patient in NIL-CDNP-CT005, an open-label, single-blind, placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure, or ADHF. The study was designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with ADHF and mild to moderate renal insufficiency.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bradford Craig Lipman, MD 1605 Roberta Dr Sw, Marietta, GA 30008-3855 Ph: (770) 419-3120 | Dr Bradford Craig Lipman, MD 1605 Roberta Dr Sw, Marietta, GA 30008-3855 Ph: (770) 419-3120 |
News Archive
As critical care professionals develop a better understanding of the progression of H1N1, they are becoming better prepared to treat children with severe cases, according to a new study that will be published in the March issue of Pediatric Critical Care Medicine (PCCM).
Apria Healthcare Group Inc. (the "Issuer") announced today that it is commencing exchange offers for all of its outstanding 11.25% Senior Secured Notes due 2014 (Series A-1) (the "Outstanding Series A-1 Notes") and 12.375% Senior Secured Notes due 2014 (Series A-2) (the "Outstanding Series A-2 Notes" and, together with Outstanding Series A-1 Notes, the "Outstanding Notes"), upon the terms and conditions set forth in a prospectus, dated August 16, 2010, and in the accompanying letter of transmittal relating to the exchange offers.
Isis Pharmaceuticals, Inc. announced today that it has earned a $10 million milestone payment from Biogen Idec related to the initiation of investigational new drug (IND)-supporting studies of ISIS-BIIB3Rx. ISIS-BIIB3Rx is a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease.
Nile Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that it has completed the dosing of the last patient in NIL-CDNP-CT005, an open-label, single-blind, placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure, or ADHF. The study was designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with ADHF and mild to moderate renal insufficiency.
› Verified 5 days ago
Anu Kurl, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 400 Tower Rd Ne Ste 160, Marietta, GA 30060 Phone: 770-420-1690 Fax: 770-420-1661 | |
Dr. Sharon M Odell, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 54 Tower Rd Ne, Marietta, GA 30060 Phone: 770-427-4682 Fax: 770-499-8562 | |
Dr. Helga Annalina Bahr, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 580 Atlanta Country Club Drive, Marietta, GA 30068 Phone: 770-988-8554 | |
Dr. Kaynessa Celena Providence, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 54 Tower Rd Ne, Marietta, GA 30060 Phone: 770-427-4682 Fax: 770-499-8562 | |
Dr. Ryan V Cantwell, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 320 Kennestone Hospital Blvd, Suite 201, Marietta, GA 30060 Phone: 770-427-2457 Fax: 770-427-2706 | |
Dr. Joanne Zhiwen Zhu, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 677 Church St Ne # 111, Marietta, GA 30060 Phone: 770-793-7750 | |
Asif A Saberi, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 55 Whitcher St Ne, Suite 160, Marietta, GA 30060 Phone: 770-422-1372 Fax: 770-423-9651 |